Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions

被引：8

作者：

Adán A. ^{[1
]}

Hernandez V. ^{[2
]}

Ortiz S. ^{[1
]}

Molina J.J. ^{[1
]}

Pelegrin L. ^{[1
]}

Espinosa G. ^{[3
]}

Sanmartí R. ^{[2
]}

机构：

[1] Department of Ophthalmology, Hospital Clinic de Barcelona, Universidad de Barcelona, Barcelona 08036, Calle Sabino de Arana

[2] Department of Rheumatology, Hospital Clinic de Barcelona, Universidad de Barcelona, Barcelona

[3] Department of Autoimmune Diseases, Hospital Clinic de Barcelona, Universidad de Barcelona, Barcelona

来源：

International Ophthalmology | 2010年 / 30卷 / 5期

关键词：

Behçet disease; Infliximab; Uveitis;

D O I：

10.1007/s10792-010-9372-1

中图分类号：

学科分类号：

摘要：

To determine the efficacy of infliximab treatment in refractory posterior uveitis in Behçet's disease after withdrawal of infusions. Four patients with posterior uveitis secondary to Behçet's disease were treated with infliximab until complete remission and were followed after withdrawal of infusions. Intra-ocular inflammation was assessed using the binocular indirect ophthalmoscopy score, best-corrected visual acuity (BCVA) and foveal thickness measured by optic coherence tomography (OCT). All the patients included in the study were treated with infliximab for a minimum of 12 months and were in complete remission. None of the patients were taking steroids or immunosuppressants. Main follow-up after withdrawal of infusions was 7.5 months. Two out of four patients (50%) maintained complete remission of posterior uveitis. BCVA was stable in seven eyes. OCT showed worsening in macular edema in the two eyes of the patients with reactivation. Infliximab is an efficient long-term treatment for refractory posterior uveitis. Repeated infusions are required to maintain long-term remission which may be sustained on discontinuation of the drug. © 2010 Springer Science+Business Media B.V.

引用

页码：577 / 581

页数：4

共 20 条

[1] Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J., Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions, Cytokine, 7, pp. 251-259, (1995)
[2] Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., Markomichelakis N.N., Effect of infliximab on sight-threatening panuveitis in Behçet's disease, Lancet, 358, 9278, pp. 295-296, (2001)
[3] Tugal-Tutkun I., Mudun A., Urgancioglu M., Kamali S., Kasapoglu E., Inanc M., Gul A., Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: An open-label trial, Arthritis and Rheumatism, 52, 8, pp. 2478-2484, (2005)
[4] Munoz-Hernandez S., Hidalgo V., Fernandez-Melon J., Schlincker A., Martin-Mola E., Effect of infliximab on threatening panuveitis in Behçet's disease, Lancet, 358, (2001)
[5] Benitez-del-Castillo J.M., Martinez-de-la-Casa J.M., Pato-Cour E., Mendez-Fernandez R., Lopez-Abad C., Matilla M., Garcia-Sanchez J., Long-term treatment of refractory posterior uveitis with anti-TNFα (infliximab), Eye, 19, 8, pp. 841-845, (2005)
[6] Hale S., Lightman S., Anti-TNF therapies in the management of acute and chronic uveitis, Cytokine, 33, pp. 231-237, (2006)
[7] Galor A., Perez V.L., Hammel J.P., Lowder C.Y., Differential Effectiveness of Etanercept and Infliximab in the Treatment of Ocular Inflammation, Ophthalmology, 113, 12, pp. 2317-2323, (2006)
[8] Ohno S., Nakamura S., Hori S., Et al., Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis, J Rheumatol, 31, pp. 1362-1368, (2004)
[9] Accorinti M., Pirraglia M.P., Paroli M.P., Priori R., Conti F., Pivetti-Pezzi P., Infliximab treatment for ocular and extraocular manifestations of Behçet's disease, Japanese Journal of Ophthalmology, 51, 3, pp. 191-196, (2007)
[10] Toubi E., Kessel A., Mahmudov Z., Hallas K., Rozenbaum M., Rosner I., Increased spontaneous apoptosis of CD4<sup>+</sup>CD25<sup>+</sup> T cells in patients with active rheumatoid arthritis is reduced by infliximab, Annals of the New York Academy of Sciences, 1051, pp. 506-514, (2005)

← 1 2 →